> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-170/
- Published: 2018-03-11T12:00:00.000Z
- Updated: 2026-09-14T23:29:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140958

[**Doryx Not Withdrawn Due to Safety/Effectiveness: FDA**](https://www.fdaweb.com/doryx-not-withdrawn-due-to-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that Mayne Pharma International’s Doryx MPC (doxycycline hyclate), delayed-release tablets, 60 mg, were not withdrawn from sale for safety or effectiveness reasons. 03/09/2018

[**Advisory Committee Docket Number Corrected**](https://www.fdaweb.com/advisory-committee-docket-number-corrected/)  
*Federal Register* notice correction: FDA corrects a 2/22 notice entitled “Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting.” 03/08/2018

[**Class 2 for Extracorporeal Shock Wave Device**](https://www.fdaweb.com/class-2-for-extracorporeal-shock-wave-device/)  
*Federal Register* notice: FDA classifies the extracorporeal shock wave device for treating chronic wounds into Class 2 (special controls). 03/07/2018

[**Comments Sought on Device Reclassification Info Collection**](https://www.fdaweb.com/comments-sought-on-device-reclassification-info-collection/)  
*Federal Register* notice: FDA seeks comments on an information collection for “Reclassification Petitions for Medical Devices — 21 CFR Section 860.123” (OMB Control Number 0910-0138). 03/07/2018

[**Draft Guide on Drug Supply Definitions**](https://www.fdaweb.com/draft-guide-on-drug-supply-definitions/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act.” 03/05/2018

[**Comments Sought on Pediatric Drug Safety Reviews**](https://www.fdaweb.com/comments-sought-on-pediatric-drug-safety-reviews/)  
*Federal Register* notice: FDA seeks comments on post-marketing pediatric-focused safety reviews of products posted between 10/23/2017 and 3/16 on its Web site. 03/05/2018